Research progress on the differential effects of novel anti-tumor drugs on pulmonary hypertension
- VernacularTitle:新型抗肿瘤药物对肺动脉高压的差异化作用研究进展
- Author:
Congjin ZHANG
1
;
Weiping LI
1
;
Huolian QIAN
1
;
Qing QIAN
1
;
Qiang WANG
1
Author Information
1. Dept. of Pharmacy，the Second Affiliated Hospital of Army Medical University，Chongqing 400037，China
- Publication Type:Journal Article
- Keywords:
novel anti-tumor drugs;
pulmonary arterial hypertension;
imatinib;
nivolumab
- From:
China Pharmacy
2025;36(6):758-763
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary hypertension （PH） is a severe and rare chronic cardiopulmonary disorder for which existing vasodilator therapies can only alleviate symptoms， rather than target or fundamentally reverse the disease. Additionally， the long-term prognosis remains poor. Recent studies have found that some novel anti-tumor drugs （NADs） can relieve PH， such as imatinib， gefitinib， sorafenib， olaparib， piperacillin， everolimus， rituximab， etc. However， some NADs can induce PH or exacerbate its symptoms， including dasatinib， lorlatinib， carfilzomib， bevacizumab， trastuzumab， nivolumab， etc. The effects of lapatinib， ruxolitinib， and bortezomib on PAH are controversial. Individualized medication should be adopted in clinical practice when using NADs for treatment， with close monitoring being essential.
